Isomorphic Labs raises $2.1B to expand AI drug discovery platform

The new financing will be used to scale the company's drug development efforts, grow its research programs and expand its workforce. Isomorphic Labs , an AI drug discovery and development company, raised $2.1 billion in a Series B funding round led by Thrive Capital. ​The raise was also backed by existing investors Alphabet and GV (Google Ventures) and new investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund. Isomorphic Labs, launched in 2021 from Google DeepMind, uses predictive and generative AI models to power its drug discovery engine, dubbed IsoDDE (Isomorphic Labs Drug Design Engine), across multiple therapeutic areas.…

Source: MobiHealthNews